March of 1998 was a big month for Pfizer and its shareholders. That’s when the new little blue pill called Viagra was released. It was a breakthrough for the pharmaceutical industry — the first ever male performance enhancement drug. Viagra’s commercial release created a new multi-billion drug market virtually overnight. Millions of American men and women enjoyed the benefits of the drug, but the biggest winner was Pfizer shareholders. As Viagra delivered record sales month after month, Pfizer’s share price jumped 64% in 12 months. Take a look below. Today, I see this same pattern repeating itself in… Read More
March of 1998 was a big month for Pfizer and its shareholders. That’s when the new little blue pill called Viagra was released. It was a breakthrough for the pharmaceutical industry — the first ever male performance enhancement drug. Viagra’s commercial release created a new multi-billion drug market virtually overnight. Millions of American men and women enjoyed the benefits of the drug, but the biggest winner was Pfizer shareholders. As Viagra delivered record sales month after month, Pfizer’s share price jumped 64% in 12 months. Take a look below. Today, I see this same pattern repeating itself in the cannabis industry. The FDA is close to potentially approving its first ever cannabis pharmaceutical — a final ruling could happen by the end of 2017, less than 12 weeks away. #-ad_banner-#This would be a ground breaking approval for the entire pharmaceutical industry and particularly for the cannabis industry. It could also give birth to the first ever cannabis blockbuster drug. This drug could generate more than $1 billion in annual revenue. Just like Pfizer with Viagra, this drug could send shares of this promising young cannabis biotech soaring over the next 12 months. The Company Behind This Game-Changing Treatment… Read More